CAREERS AT BIOMARIN
Our focus on rare disease gives us the rare opportunity to truly impact lives.
Learn More about careers with BioMarin ⌃OUR MOTIVATION
We are inspired and driven everyday by stories like Sheri’s.
Learn More about Sheri ⌃
Patient & Community Support
Treatment is only the beginning.
We are committed to the communities we treat beyond the therapies we develop.
Learn More about our patient support ⌃OUR PIPELINE
We take on the biggest challenges in rare disease.
Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.
View Now ⌃-
February 25, 2021BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
-
February 24, 2021BioMarin to Participate in Four Upcoming Virtual Investor Conferences
-
February 18, 2021BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
-
January 28, 2021BioMarin Earns Top Marks in Human Rights Campaign’s 2021 Corporate Equality Index
-
January 26, 2021BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
-
January 10, 2021BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
-
January 5, 2021BioMarin to Participate in Two Upcoming Virtual Investor Conferences
-
December 21, 2020BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study